Placental transport of heparin

Flessa, Herbert C.; Kapstrom, Albert B.; Glueck, Helen I.; Will, John J.

doi:10.1016/0002-9378(65)90518-1

Cited by 165 publications

(50 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UFH does not cross the placenta 63 and, therefore, does not have the potential to cause fetal bleeding or teratogenicity; although bleeding at the uteroplacental junction is possible. Several studies provide high-quality evidence that UFH therapy is safe for the fetus.…”

Section: Ufh Exposure In Uteromentioning

confidence: 99%

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Bates

Greer

Middeldorp

et al. 2012

Chest

1,286

591

View full text Add to dashboard Cite

Summary of RecommendationsNote on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded. Abbreviations: APLA 5 antiphospholipid antibody; aPPT 5 activated partial thromboplastin time; HIT 5 heparin-induced thrombocytopenia; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; NNT 5 number needed to treat; PE 5 pulmonary embolism; RR 5 risk ratio; UFH 5 unfractionated heparin

show abstract

Section: Ufh Exposure In Uteromentioning

confidence: 99%

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Bates

Greer

Middeldorp

et al. 2012

Chest

1,286

591

View full text Add to dashboard Cite

show abstract

“…Both LMWH and UFH potentiate the activity of antithrombin (including anti-factor-IIa and anti-factor-Xa activity), reduce formation of thrombus, and enhance fibrinolysis [14]. Neither agent crosses the placenta [40,41]. A recent systematic review substantiated the safety and efficacy of LMWH for management of VTE in pregnancy, focusing on the reduced likelihood of bleeding, osteoporosis, and heparin-induced thrombocytopenia (HIT) in comparison to UFH [42][43][44].…”

Section: Choice Of Treatment Agentmentioning

confidence: 99%

Venous thromboembolism in obese pregnant women: approach to diagnosis and management

et al. 2017

View full text Add to dashboard Cite

Venous thromboembolism (VTE) remains among the leading causes of maternal mortality in the developed world, presenting variably as deep vein thrombosis (DVT), pulmonary embolism (PE) or cerebral vein thrombosis (CVT), among others. Obesity in particular has been recognized as the principal contributing factor to the risk of VTE in pregnancy and with the global increase in the rates of obesity affecting reproductive age women, heightened awareness of the risk and consequences of VTE in this population are vital. Thus, prophylaxis, diagnosis and treatment of VTE in the obese gravida are discussed.

show abstract

“…12,29,36) Among other antithrombotic agents used after endovascular therapy, heparin has no side effects for the fetus. 15,19) Warfarin is a well-known contraindication for pregnant and breast-feeding women, because of its teratogenic (fetal warfarin syndrome) and hemorrhagic complications. 4,30,38) Description on Package Leaflet: Alteplase for Pregnant Women…”

Section: Treatment Strategy For Acute Ischemic Stroke In Pregnancymentioning

confidence: 99%

Acute Revascularization Therapy in Pregnant Patients

Hirano

2013

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Ischemic stroke is uncommon during pregnancy, but decision making for acute revascularization therapy including intravenous recombinant tissue plasminogen activator (rt-PA) is difficult. The use of rt-PA remains controversial, but a systematic review of 16 patients (mean age 31.7 years) showed good results for both maternal (77.8%) and fetal (56.3%) outcomes. Pregnancy alone is not a solid contraindication for acute revascularization therapy including rt-PA. An endovascular approach might be beneficial for reducing the hemorrhagic complication; however, the treatment strategy should be considered based on the available treatment facility. Close cooperation with obstetrics is essential for the successful management of saving the lives of both the mother and the fetus.

show abstract

Placental transport of heparin

Cited by 165 publications

References 4 publications

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Venous thromboembolism in obese pregnant women: approach to diagnosis and management

Acute Revascularization Therapy in Pregnant Patients

Contact Info

Product

Resources

About